Overview
AKTS market data
Price History
AKTS price chart · 1M
- O
- 26.51
- H
- 27.18
- L
- 26.51
- C
- 27.10
- Vol
- 9,768.00
- Source
- US equities market feed
- Observed
- Cadence
- Five-minute page cache; daily and stored hourly bars
- Status
- fresh
Key Stats & Performance
- Open
- $26.51
- Previous Close
- $26.53
- Day High
- $27.18
- Day Low
- $26.51
- 52 Week High
- $34.07
- 52 Week Low
- $17.92
- 7 Day Return
- +5.24%
- 30 Day Return
- +19.70%
- 90 Day Return
- +43.08%
- 1 Year Return
- +48.45%
- Daily Notional Volume
- $264.7K Latest daily bar volume multiplied by its closing price.
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$1.26 Diluted earnings per share over the trailing twelve months.
- Beta
- 164.55 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- -810.2% Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $14.72 – $34.19 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $1.5B · P/B 5.88 · P/S 113.08.
Company News
8 captured
Wedbush Initiates Coverage On Aktis Oncology with Outperform Rating, Announces Price Target of $35Benzinga ·
Aktis Oncology Q2 EPS $(0.44) Misses $(0.43) Estimate, Sales $3.384M Beat $2.000M EstimateBenzinga ·